Large-Scale Drug Screening in Patient-Derived IDH<sup>mut</sup> Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents

Large-Scale Drug Screening in Patient-Derived IDH<sup>mut</sup> Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents

The discovery of the isocitrate dehydrogenase (IDH) mutation in glioma led to a paradigm shift on how we see glioma biology. Difficulties in cultivating IDH mutant glioma stem cells (IDH<sup>mut</sup> GSCs) resulted in a paucity of preclinical models in IDH<sup>mut</sup> glio...

Full description

Bibliographic Details
Main Authors: Philip Dao Trong, Gerhard Jungwirth, Tao Yu, Stefan Pusch, Andreas Unterberg, Christel Herold-Mende, Rolf Warta
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cells
Subjects:
drug screen
lower grade glioma
isocitrate dehydrogenase (IDH) mutant glioma stem cells
bortezomib
carfilzomib
daunorubicin
Online Access:https://www.mdpi.com/2073-4409/9/6/1389

Internet

https://www.mdpi.com/2073-4409/9/6/1389

Similar Items